ALT5 Sigma (AIFC) & Its Competitors Critical Contrast

ALT5 Sigma (NASDAQ:AIFC) is one of 345 public companies in the “Financial Services” industry, but how does it weigh in compared to its rivals? We will compare ALT5 Sigma to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares ALT5 Sigma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-4,021.65%	-51.87%	-48.30%
ALT5 Sigma Competitors	-405.72%	-21.94%	-5.68%

Institutional & Insider Ownership

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 21.8% of shares of all “Financial Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ALT5 Sigma and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
ALT5 Sigma Competitors	1903	6818	11530	414	2.51

As a group, “Financial Services” companies have a potential upside of 3.80%. Given ALT5 Sigma’s rivals stronger consensus rating and higher probable upside, analysts clearly believe ALT5 Sigma has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares ALT5 Sigma and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ALT5 Sigma	$24.84 million	-$344.51 million	1.21
ALT5 Sigma Competitors	$6.31 billion	$1.08 billion	8.51

ALT5 Sigma’s rivals have higher revenue and earnings than ALT5 Sigma. ALT5 Sigma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

ALT5 Sigma has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, ALT5 Sigma’s rivals have a beta of 2.26, indicating that their average share price is 126% more volatile than the S&P 500.

Summary

ALT5 Sigma rivals beat ALT5 Sigma on 13 of the 13 factors compared.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.